Neue Studien: Europe PMChttps://www.psoriasis-news.de/articles.html/1_articles/?d=1Neue Studien: Europe PMCdeFactors Associated With PASI90 Maintenance Without Flare-Up and Predictors of Biologics Discontinuation in Psoriasis: Two-Center Retrospective Cohort Study in Korea.https://www.psoriasis-news.de/articles.html/1_articles/factors-associated-with-pasi90-maintenance-without-flare-up-and-predictors-of-biologics-discontinuation-in-psoriasis-two-center-retrospective-cohort-study-in-korea-r703/BackgroundBiologics targeting key cytokines have enabled near-complete clearance in psoriasis treatment. As 90% reduction in the Psoriasis Area and Severity Index (PASI90) emerges as a meaningful goal of treatment, maintaining PASI90 without flare-up has become important.

Objective

To identify factors associated with PASI90 maintenance for ≥1 year without flare-up and predictors of drug discontinuation.

Methods

This multicenter retrospective cohort study included moderate-to-severe plaque psoriasis patients treated with adalimumab, ustekinumab, secukinumab, ixekizumab, guselkumab, or risankizumab (2010-2022). Treatment courses were defined as "Episodes." Patients with ≥2 years of therapy were analyzed. Relative risks (RR) for PASI90 maintenance were estimated using generalized linear mixed models, and Cox proportional hazards models assessed drug discontinuation.

Results

Among 136 patients (189 episodes), 40.1% of 162 eligible episodes achieved PASI90 maintenance without flare-up for ≥1 year. Secukinumab significantly increased the likelihood of PASI90 maintenance (RR, 2.1; 95% confidence interval [CI], 1.27-3.49). Body mass index (BMI) <30 and first biologic episode showed favorable with only trend toward significance. Psoriasis Area and Severity Index response at week 16 and first assessment strongly predicted maintenance (area under the curve, 0.80-0.82). Regarding drug discontinuation, drug were discontinued in 28.6% of episodes; BMI ≥30, family history of psoriasis, and adalimumab (hazard ratio, 4.50; 95% CI, 1.57-12.90 vs. ustekinumab) were associated with higher risk of drug discontinuation.

Conclusion

Secukinumab, lower BMI, and biologic-naïve status favored durable PASI90 without flare-up. Obesity, family history, and adalimumab predicted drug discontinuation. Early treatment response strongly predicted long-term efficacy.

Weiterlesen

]]>703Mon, 10 Aug 2026 05:35:26 +0000Patients with Psoriatic Arthritis Have Increased Dental Comorbidities: A Nationwide Population-based Cohort Study in Korea.https://www.psoriasis-news.de/articles.html/1_articles/patients-with-psoriatic-arthritis-have-increased-dental-comorbidities-a-nationwide-population-based-cohort-study-in-korea-r702/Weiterlesen

]]>702Mon, 10 Aug 2026 05:35:26 +0000Impact of Intermittent Fasting, Keto Diet vs Continuous Caloric Restriction on Psoriasis Severity: A Systematic Review and Meta-Analysis Protocol.https://www.psoriasis-news.de/articles.html/1_articles/impact-of-intermittent-fasting-keto-diet-vs-continuous-caloric-restriction-on-psoriasis-severity-a-systematic-review-and-meta-analysis-protocol-r701/BackgroundPsoriasis is a chronic immune‑mediated inflammatory skin disease that is strongly associated with metabolic dysregulation and excess adiposity. Dietary strategies that reduce energy intake either by continuous daily caloric restriction (CCR) or time‑limited/periodic intake such as intermittent fasting (IF) or ketogenic diets (Keto) may improve psoriasis severity through weight loss, metabolic improvements, alterations in gut microbiota, and immune-metabolic effects.

Objective

We aimed to compare the therapeutic effectiveness of IF, Keto, and CCR in reducing the severity of psoriasis.

Methods

This study was designed as a systematic review and Meta Analysis. The clinical parameters such as psoriasis extent and outcome measures were evaluated at baseline at different follow up timeframes across studies. Outcome measures were assessed by changes in Psoriasis Area and Severity Index (PASI) scores, quality of life (dermatology life quality index [DLQI]), and metabolic scores.

Results

There was a significant PASI decrease in Keto and CCR cohorts (10-25.6 kg weight loss) compared with IF (0-2kg weight loss). No serious adverse effects were recorded in all interventions.

Limitations

The major limitations were study heterogeneity, lack of head-to-head comparisons, and follow up.

Conclusion

CCR and Keto performed better than IF in managing psoriasis severity, suggesting personalized dietary routines as adjuncts to treatment. &nbsp.

Weiterlesen

]]>701Mon, 10 Aug 2026 05:35:26 +0000Efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis with a high drug interruption rate during the COVID-19 pandemic: a post hoc analysis from a single center of a phase III trial.https://www.psoriasis-news.de/articles.html/1_articles/efficacy-and-safety-of-vunakizumab-in-patients-with-moderate-to-severe-plaque-psoriasis-with-a-high-drug-interruption-rate-during-the-covid-19-pandemic-a-post-hoc-analysis-from-a-single-center-of-a-phase-iii-trial-r700/Weiterlesen

]]>700Mon, 10 Aug 2026 05:35:26 +0000Impact of Psoriasis on Patient Well-Being Across Life Stages: A Cross-Sectional Survey (Inpsight Working Group).https://www.psoriasis-news.de/articles.html/1_articles/impact-of-psoriasis-on-patient-well-being-across-life-stages-a-cross-sectional-survey-inpsight-working-group-r699/BackgroundPsoriasis is a chronic disease with a multidimensional impact that extends beyond skin symptoms, affecting physical, emotional, social well-being and satisfaction with care. This study aims to explore the perceived self-reported impact of psoriasis on patients' well-being across different life stages and to identify risk and protective factors associated with well-being over time.

Methods

A cross-sectional observational study was conducted using an electronic questionnaire administered to adult patients with psoriasis and healthcare professionals involved in psoriasis management. Patients retrospectively self-reported the perceived impact of psoriasis on overall well-being and its physical, emotional, social, and treatment-related domains across consecutive 10-year life stages. Both patients and healthcare professionals evaluated perceived risk and protective factors for well-being.

Results

A total of 53 patients and 54 healthcare professionals completed the questionnaire. Most patients (90.6%) reported psoriasis had negatively affected their general well-being at some point during the disease course, with the physical (90.6%) and emotional (88.7%) domains being the most impacted. The highest perceived burden was reported between 31 and 40 years of age. Better reported symptom control was associated with lower perceived impairment in well-being. Key risk factors included affected body areas (95.3%), comorbidities (93.5%), and disease severity (89.7%), whereas appropriate treatment (96.3%), adequate medical care (93.5%), and a positive physician-patient relationship (89.7%) were identified as protective factors.

Conclusion

These exploratory findings suggest that the self-reported perceived impact of psoriasis on well-being varies across life stages and is strongly influenced by symptom control and holistic disease management. These findings support a longitudinal, patient-centered approach to optimize long-term well-being.

Weiterlesen

]]>699Mon, 10 Aug 2026 05:35:26 +0000Real-World Effectiveness and Safety of Deucravacitinib for Plaque Psoriasis: A Multicenter Study in Korea.https://www.psoriasis-news.de/articles.html/1_articles/real-world-effectiveness-and-safety-of-deucravacitinib-for-plaque-psoriasis-a-multicenter-study-in-korea-r698/BackgroundDeucravacitinib, an oral tyrosine kinase 2 inhibitor, has demonstrated efficacy and safety in clinical trials; however, real-world evidence remains limited.

Objective

To evaluate real-world effectiveness, safety, and treatment persistence of deucravacitinib in Korean patients with plaque psoriasis.

Methods

This retrospective multicenter study included adults with plaque psoriasis treated with deucravacitinib at 3 tertiary hospitals. Efficacy was assessed using Psoriasis Area and Severity Index (PASI), body surface area, and Psoriasis Scalp Severity Index at baseline, 4-6, 10-12, and ≥13 months. PASI75 and PASI90 responses were analyzed using observed case (OC) and modified non-responder imputation (mNRI). Adverse events (AEs) and persistence were analyzed descriptively. Univariable and multivariable logistic regression analyses were performed to identify predictors of efficacy and AEs.

Results

Forty-two patients (baseline PASI: 12.18±4.01) were included. PASI score decreased significantly to 3.42±3.10 at 4-6 months and 1.72±2.29 at 10-12 months. At 10-12 months, PASI75 and PASI90 response rates were 90.0% and 70.0% (OC; 18/20 and 14/20), and 75.0% and 58.3% (mNRI; 18/24 and 14/24). Thirteen patients (31.0%) reported AEs, primarily mucocutaneous and infectious; 3 patients discontinued deucravacitinib due to AEs. In both univariable and exploratory multivariable analyses, prior antihistamine use showed consistent borderline trends for PASI75 response, while male sex, increasing age, and shorter psoriasis duration showed borderline trends in either model. Treatment persistence was 73.2% at the last follow-up.

Conclusion

Deucravacitinib demonstrated consistent effectiveness, acceptable safety, and favorable persistence in routine Korean clinical practice, supporting its role as an oral treatment option for psoriasis.

Weiterlesen

]]>698Mon, 10 Aug 2026 05:35:26 +0000Tape-strip transcriptomics identify immune signatures in cutaneous T-cell lymphoma distinct from benign inflammatory skin diseases.https://www.psoriasis-news.de/articles.html/1_articles/tape-strip-transcriptomics-identify-immune-signatures-in-cutaneous-t-cell-lymphoma-distinct-from-benign-inflammatory-skin-diseases-r697/BackgroundPrimary cutaneous T-lymphomas (CTCL), particularly in their early stages, frequently present with clinical and histopathologic features that overlap with atopic dermatitis (AD) and psoriasis, contributing to diagnostic delay and ineffective, or even deleterious, treatment approaches. Thus, minimally invasive molecular tests capable of distinguishing CTCL from benign inflammatory dermatoses are urgently needed.

Objectives

To determine whether tape strip transcriptomics can detect disease-specific signatures distinguishing early-stage CTCL from AD, psoriasis, and healthy control (HC) skin.

Methods

Bulk RNA sequencing was performed on lesional and non-lesional tape strips from patients with mycosis fungoides (MF) (n=18), AD (n=36), psoriasis (n=32), and HC skin (n=30).

Results

Principal component analysis revealed distinct clustering of MF, AD, and psoriasis lesional skin relative to HC. MF displayed a mixed immune profile, contrasting with the strong Th2 and Th17/Th22 immune polarization of AD and psoriasis, respectively. Upregulated MF genes were involved in immune checkpoint regulation (CTLA4, ICOS), lymphoid trafficking (CCR7, CCR8), antigen presentation (HLA-DRA, LAMP3), T-cell survival (TNFSF13B, BIRC3), metabolism (BCAT1, ENPP4, LIPA), as well as cell structure and homeostasis (CLIC2, DOCK10, EPB41L3, MCOLN2, MS4A14, S100B). We identified a 5-marker gene classifier (including IL36A) that accurately distinguished MF from both AD and psoriasis, which was validated in an independent dataset.

Conclusions

By capturing MF-specific signatures that are distinct from AD and psoriasis, tape stripping has the potential to serve as a diagnostic tool to help differentiate MF from its non-malignant mimickers.

Weiterlesen

]]>697Mon, 10 Aug 2026 05:35:26 +0000Decreased Nonmelanoma Skin Cancer Risk With Interleukin-17 and Interleukin-23 Inhibitors Versus TNF-α Inhibitors in Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/decreased-nonmelanoma-skin-cancer-risk-with-interleukin-17-and-interleukin-23-inhibitors-versus-tnf-%CE%B1-inhibitors-in-psoriasis-r696/BackgroundPeople with psoriasis are at increased risk for nonmelanoma skin cancers (NMSC) and melanoma. Conventional immunosuppressants and TNF-α inhibitors may further increase skin malignancies, while the risks associated with other biologics are less clear. This study aimed to determine skin malignancy risks in psoriasis patients treated with cyclosporine, methotrexate, TNF-α inhibitors, IL-12/23, IL-17, and IL-23 inhibitors.

Methods

Using the TriNetX database, psoriasis patients without skin cancer risk factors who received at least 2 years or at least 5 years of systemic treatment were compared with non-systemically treated psoriasis patients. Cyclosporine, methotrexate, and TNF-α inhibitors were also compared with other psoriasis biologics. NMSC and melanoma over 2 and 5 years were evaluated using multivariable Cox proportional hazards.

Results

Compared with non-systemically treated psoriasis patients, cyclosporine, methotrexate, TNF-α inhibitors, and the IL-12/23 inhibitor showed increased NMSC risk, whereas IL-17 inhibitors demonstrated a reduced risk. Compared with patients treated with cyclosporine, methotrexate, and TNF-α inhibitors, both IL-17 and IL-23 inhibitors demonstrated a reduced NMSC risk. Only cyclosporine was associated with elevated melanoma risk. The present study is limited by unmeasured factors, including psoriasis severity, ultraviolet radiation exposure, medication adherence, and dosing.

Conclusions

Systemic therapies for psoriasis vary in skin malignancy risk, with IL-17 and IL-23 inhibitors having the lowest NMSC risk. &nbsp.

Weiterlesen

]]>696Mon, 10 Aug 2026 05:35:26 +0000Medication use during pregnancy and pregnancy outcomes in women with immune mediated inflammatory diseases: a UK-based matched cohort study.https://www.psoriasis-news.de/articles.html/1_articles/medication-use-during-pregnancy-and-pregnancy-outcomes-in-women-with-immune-mediated-inflammatory-diseases-a-uk-based-matched-cohort-study-r695/ObjectivesImmune mediated inflammatory diseases (IMID) affect women of childbearing age, yet there is a lack of evidence about the risk of adverse pregnancy outcomes and the interaction with medication. This study aims to characterise prescribing patterns and pregnancy outcomes in women with an IMID diagnosis.

Methods

Pregnancies to women with rheumatoid arthritis (RA), psoriatic arthritis (PsA), psoriasis (PsO), spondyloarthritis (SpA) and inflammatory bowel disease (IBD) were identified within the Clinical Practice Research Datalink, between 01-Jan-2000 and 31-Jun-2020, and matched to pregnancies in women with no such diagnosis. Drug prescribing patterns were described during and surrounding pregnancy. The risk of spontaneous pregnancy loss and major congenital malformations (MCMs) were evaluated compared to women without an IMID. Exposure to commonly prescribed disease-modifying anti-rheumatic drugs was evaluated.

Results

The risk of a spontaneous pregnancy loss ranged from HRadj 1.01 (CI950.79-1.28) for PsA to HRadj 1.18 (CI951.07-1.30) for IBD when compared to women without these conditions. No significant increases in the overall risk of MCMs were observed, with the exception of IBD where it reached borderline significance based on sensitivity analyses (ORadj 1.31 (CI951.00-1.71). No evidence of an increased risk of spontaneous loss was observed in women taking azathioprine, mesalazine and sulfasalazine.

Conclusion

We found no increased risk of spontaneous loss in women with RA, PsA or SpA but a small increase in women with psoriasis or IBD. There was a borderline increased risk of all MCMs in offspring of women with IBD, which should be interpreted cautiously because of potential residual confounding.

Weiterlesen

]]>695Mon, 10 Aug 2026 05:35:26 +0000The Definition of Psoriasis Severity and Treatment Target of Psoriasis: Korean Expert Consensus Using the Modified Delphi Method.https://www.psoriasis-news.de/articles.html/1_articles/the-definition-of-psoriasis-severity-and-treatment-target-of-psoriasis-korean-expert-consensus-using-the-modified-delphi-method-r694/BackgroundThe emergence of new treatments has significantly elevated treatment expectations for psoriasis. However, existing Korean severity definitions and treatment targets of psoriasis remain primarily centered on traditional Psoriasis Area and Severity Index (PASI) and Body Surface Area (BSA) thresholds, often underestimating the disease burden in high-impact special areas.

Objective

To develop a revised Korean expert consensus on psoriasis severity and treatment targets that incorporate the clinical significance of special areas and reflect the evolving therapeutic landscape.

Methods

A modified Delphi method was employed involving a panel of 65 dermatologists specializing in psoriasis from universities and training hospitals across South Korea. Two rounds of anonymous web-based surveys were conducted.

Results

A strong consensus was achieved on a new definition of moderate-to-severe psoriasis: (1) PASI ≥10, or (2) 5< PASI <10 with concomitant special area involvement (defined as ≥30% affected surface area of the specific site and a static Physician's Global Assessment (sPGA) score ≥3). For treatment targets, the panel established 'Absolute PASI ≤2' as the primary realistic goal. Site-specific goals were defined for special areas, to achieve an affected surface area <10% or an sPGA of 0/1. The Dermatology Life Quality Index was excluded from the mandatory severity definition or treatment target to preserve objectivity and feasibility in high-volume clinical settings.

Conclusion

This consensus provides a practical and objective framework for managing psoriasis in Korea. These recommendations provide quantifiable criteria and stringent targets to optimize clinical decisions and patient outcomes in the era of advanced therapeutics.

Weiterlesen

]]>694Mon, 10 Aug 2026 05:35:26 +0000Assessment of Major Adverse Cardiovascular Event Across Diverse Racial Groups of Psoriasis Patients on Biologic Therapy: A Retrospective Cohort Study.https://www.psoriasis-news.de/articles.html/1_articles/assessment-of-major-adverse-cardiovascular-event-across-diverse-racial-groups-of-psoriasis-patients-on-biologic-therapy-a-retrospective-cohort-study-r693/Weiterlesen

]]>693Thu, 30 Jul 2026 05:12:07 +0000A randomized phase 2 trial of socrodeucitinib in moderate-to-severe plaque psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/a-randomized-phase-2-trial-of-socrodeucitinib-in-moderate-to-severe-plaque-psoriasis-r692/BackgroundTyrosine kinase 2 (TYK2), a key part of the inflammatory cascade responses, plays an integral role in the pathogenesis of psoriasis. Socrodeucitinib, an oral, TYK2 allosteric inhibitor, selectively inhibits TYK2 cytokine signalling pathways in psoriasis pathogenesis.

Objectives

To evaluate the efficacy and safety of socrodeucitinib in patients with moderate-to-severe plaque psoriasis.

Methods

In this phase 2, double-blind, placebo-controlled trial, 125 patients were randomly assigned (1:1:1) to receive socrodeucitinib at 6 mg, 12 mg or placebo orally, once daily, for 12 weeks. The primary endpoint was the proportion of patients with a 75% or greater reduction from the baseline in the Psoriasis Area and Severity Index (PASI) score at week 12.

Results

At week 12, significantly more patients treated with socrodeucitinib achieved a 75% reduction from baseline in PASI score compared with placebo (28.6% at 6 mg, 72.1% at 12 mg vs. 7.5% for placebo, p < 0.05 and p < 0.001, respectively). At the 12 mg dose, socrodeucitinib resulted in significantly higher response rates compared to placebo, with 46.5% of patients achieving PASI 90 (p < 0.001) and 11.6% achieving PASI 100 (p < 0.05). The treatment of socrodeucitinib also led to significantly higher proportions of patients achieving sPGA responses of 0 or 1 compared to placebo: 33.3% at 6 mg and 65.1% at 12 mg versus 10% for placebo (p < 0.05 and p < 0.001, respectively). Most common adverse events included upper respiratory tract infection which demonstrated a certain dose dependency. Most treatment-related adverse events were mild or moderate, and serious adverse events were infrequent, with no clinically meaningful abnormal trend in laboratory parameters.

Conclusions

Socrodeucitinib demonstrated significantly greater clearing of psoriasis plaques compared to placebo in patients with moderate-to-severe plaque psoriasis and illustrated a favourable safety and tolerability profile, warranting further investigation in longer-duration and larger trials.

Weiterlesen

]]>692Thu, 30 Jul 2026 05:12:07 +0000Investigational interleukin 17A antagonists in the treatment of psoriatic arthritis.https://www.psoriasis-news.de/articles.html/1_articles/investigational-interleukin-17a-antagonists-in-the-treatment-of-psoriatic-arthritis-r691/IntroductionThe global burden of psoriatic arthritis (PsA) is considerable, with major effects on both quality of life and life expectancy. Despite the existence of a diverse array of therapeutic interventions, approximately 40-50% of patients do not achieve the established therapeutic targets. Challenges related to tolerance, compliance, and therapeutic escape persist.

Areas covered

This study is a comprehensive review of the current literature analyzing the central role of interleukin-17 (IL-17) in the pathogenesis of PsA and emphasizing current and investigational therapies for IL-17A blockade. A structured search was conducted in PubMed for the following terms investigational IL-17A antagonist and Psoriatic arthritis. We aimed for at least 100 research papers published within the last 20 years. In addition, clinical trials databases focusing on phase II - III IL-17A antagonists treatment in Psoriatic Arthritis were also reviewed.

Expert opinion

The current stage of development and expansion of IL-17A antagonists encompasses the third generation of such molecules. This generation includes small, injectable molecules such as sonelokimab and izokibep; oral molecules; and bispecific monoclonal antibodies. This approach is purported to facilitate enhanced tissue diffusion, augmented efficacy in refractory forms, and simplified utilization. The future of PsA treatments is contingent upon the implementation of precision medicine, which leverages predictive biomarkers to personalize treatment from the moment of diagnosis. This could help control disease early and prevent progression, beyond the current Treat-to-Target strategy which mainly focuses on managing existing symptoms. The overarching objective is no longer to treat to target, but rather to treat to intercept, while ensuring the highest rate of control and tolerance for the patient.

Weiterlesen

]]>691Thu, 30 Jul 2026 05:12:07 +0000Clove oil in combination with flurbiprofen attenuated imiquimod-induced psoriasis-like skin inflammation in a mouse model: A mechanistic study.https://www.psoriasis-news.de/articles.html/1_articles/clove-oil-in-combination-with-flurbiprofen-attenuated-imiquimod-induced-psoriasis-like-skin-inflammation-in-a-mouse-model-a-mechanistic-study-r690/® ointment, a standard drug) for the next 7 days. Disease induction and treatment responses were assessed based on modified psoriasis area and severity index (modified PASI) score. On day 15, animals were euthanised, and blood and skin samples were collected for biochemical and histopathological analyses, along with a quantitative assessment of psoriasis-associated inflammatory gene expression using RT-qPCR techniques. Phytochemical tests were performed to detect total tannin, flavonoid, phenolic, and saponin contents of CO. CO 20% and FBR 5% combination and betasalic ointment treatments resulted in a significant (p < 0.05) reduction in erythema, scaling, and skin thickness with an overall modified PASI score of 4.5 ± 0.29 and 4.33 ± 0.33 when compared with the DC group (PASI score = 12 ± 00). Complete blood count analysis revealed a significant reduction (p < 0.05) in total leukocytes, neutrophils, and lymphocytes counts in the CO 20% and FBR 5% combination and betasalic ointment treated groups as compared with DC group. Moreover, a significant decrease in the spleen-to-body weight index (SBWI) was observed in the CO 20% and FBR 5% combination and betasalic ointment treated groups as compared with SBWI of DC group, highlighting the potential immune regulatory properties of CO and FBR. Histopathological analysis of skin tissues revealed a significant improvement in epidermal architecture and a reduction in inflammatory cells infiltration in the treated groups. RT-qPCR analysis revealed down-regulation in the mRNA expression of pro-inflammatory and oxidative stress-inducing genes. Phytochemical analyses confirmed the presence of flavonoids, tannins, phenolic compounds, and saponins in the CO. Overall, these findings suggest that the clove oil-flurbiprofen combination has the potential to reduce skin inflammatory conditions possibly via modulation of oxidative and inflammatory pathways.

Weiterlesen

]]>690Thu, 30 Jul 2026 05:12:07 +0000Long-Term Effectiveness of Upadacitinib in Difficult-to-Treat Psoriatic Arthritis: A 104-week Real-World Clinical and Ultrasound Study.https://www.psoriasis-news.de/articles.html/1_articles/long-term-effectiveness-of-upadacitinib-in-difficult-to-treat-psoriatic-arthritis-a-104-week-real-world-clinical-and-ultrasound-study-r689/BackgroundDifficult-to-treat psoriatic arthritis (D2T PsA) represents a challenging condition characterized by inadequate response to multiple therapeutic agents. Real-world data on the effectiveness of Janus kinase inhibitors (JAKi) in this population remain limited.

Objective

To evaluate the effectiveness, safety, and treatment persistence of Upadacitinib (UPA) in patients with D2T PsA using both clinical and ultrasound assessments.

Patients and methods

This observational retrospective study included patients with PsA who failed at least one conventional DMARD and two biologic DMARDs with different mechanisms of action. All patients received UPA 15 mg once daily as monotherapy. Treatment persistence was assessed over 140 weeks, while effectiveness data were collected at four time points following baseline (12, 24, 48, and 104 weeks). Clinical measures included: PASI; cDAPSA score; swollen/tender joints count; assessment of enthesitis and dactylitis; VAS scores for disease activity/pain; HAQ. At baseline and during the follow-up, ultrasound imaging was performed according to the EULAR-OMERACT ultrasound score.

Results

Twenty-five patients were enrolled. After 140 weeks, treatment persistence was 68%. A rapid and sustained improvement in disease activity was observed, with mean cDAPSA decreasing from 27.88±5.2 at baseline to 12.04±8.17 at week 12 and 4.88±4.54 at week 52. At one year, 70.6% of patients achieved complete remission and 23.6% low disease activity. Ultrasound findings confirmed the clinical improvement, with a significant reduction in the EULAR-OMERACT score and complete resolution of enthesitis after one year of treatment. Most patients (94.1%) maintained complete remission or low disease activity up to week 104. Skin condition also improved significantly as demonstrated by the marked reduction in PASI score which decreased from a baseline value of 2.22 ± 2.62 to 0.21 ± 0.36 after 52 weeks of treatment. The safety profile was favorable, with mild lipid and CPK abnormalities being the most common adverse events.

Conclusion

In this real-world cohort of patients with D2T PsA, UPA demonstrated sustained clinical and ultrasound effectiveness with a favorable safety profile and good long-term treatment persistence.

Weiterlesen

]]>689Thu, 30 Jul 2026 05:12:07 +0000From the Perspective of the Peripheral Sensory Nervous System: The Role of Vitamin D in Neurogenic Inflammatory Skin Disorders.https://www.psoriasis-news.de/articles.html/1_articles/from-the-perspective-of-the-peripheral-sensory-nervous-system-the-role-of-vitamin-d-in-neurogenic-inflammatory-skin-disorders-r688/Weiterlesen

]]>688Thu, 30 Jul 2026 05:12:07 +0000Unveiling the transcriptomic landscape of coronavirus disease 2019 and psoriasis via systems biology-based analysis.https://www.psoriasis-news.de/articles.html/1_articles/unveiling-the-transcriptomic-landscape-of-coronavirus-disease-2019-and-psoriasis-via-systems-biology-based-analysis-r687/Weiterlesen

]]>687Thu, 30 Jul 2026 05:12:07 +0000Dermatological Disease at a Tertiary Military Hospital in Burundi: A Retrospective Review.https://www.psoriasis-news.de/articles.html/1_articles/dermatological-disease-at-a-tertiary-military-hospital-in-burundi-a-retrospective-review-r686/No abstract supplied.

Weiterlesen

]]>686Thu, 30 Jul 2026 05:12:07 +0000Treatment Patterns and Pathways of Systemic Drug Therapy in Patients With Plaque, Erythrodermic, and Generalized Pustular Psoriasis: A Retrospective Cohort Study in Japan.https://www.psoriasis-news.de/articles.html/1_articles/treatment-patterns-and-pathways-of-systemic-drug-therapy-in-patients-with-plaque-erythrodermic-and-generalized-pustular-psoriasis-a-retrospective-cohort-study-in-japan-r685/Weiterlesen

]]>685Thu, 30 Jul 2026 05:12:07 +0000Multi-omics Mendelian randomization identified adaptive immune response-related drug targets in psoriatic arthritis.https://www.psoriasis-news.de/articles.html/1_articles/multi-omics-mendelian-randomization-identified-adaptive-immune-response-related-drug-targets-in-psoriatic-arthritis-r684/Weiterlesen

]]>684Thu, 30 Jul 2026 05:12:07 +0000Disease context dictates the cellular targets of IL-17 in inflammatory skin disease.https://www.psoriasis-news.de/articles.html/1_articles/disease-context-dictates-the-cellular-targets-of-il-17-in-inflammatory-skin-disease-r683/Weiterlesen

]]>683Tue, 28 Jul 2026 06:39:05 +0000Real-World Dose Adjustment and Switching of Interleukin-17/23 Inhibitors for Thai Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/real-world-dose-adjustment-and-switching-of-interleukin-1723-inhibitors-for-thai-psoriasis-r682/Weiterlesen

]]>682Tue, 28 Jul 2026 06:39:05 +0000Sequencing and switching among IL-17 and IL-23 biologics in plaque psoriasis: real-world lessons and precision strategies for the future.https://www.psoriasis-news.de/articles.html/1_articles/sequencing-and-switching-among-il-17-and-il-23-biologics-in-plaque-psoriasis-real-world-lessons-and-precision-strategies-for-the-future-r681/IntroductionThe therapeutic landscape of moderate-to-severe plaque psoriasis has been transformed by interleukin-17 (IL-17) and interleukin-23 (IL-23) inhibitors, which offer superior effectiveness compared to older biologics. However, a substantial proportion of patients experience primary or secondary treatment failure, necessitating a therapeutic switching.

Areas covered

This review integrates real-world evidence from studies identified through a PubMed search for publications on sequencing and switching between IL-17 and IL-23 inhibitors in plaque psoriasis. The most relevant studies were selected, and their clinical outcomes were evaluated to provide an overview of current evidence on switching strategies.

Expert opinion

Key findings indicate that interclass switching (between IL-17 and IL-23 pathways) generally outperforms intraclass switching, with IL-23 inhibitors demonstrating robust effectiveness after IL-17 failure and vice versa. Safety profiles are favorable across all switching scenarios. Future directions include biomarker-guided selection and precision medicine approaches to optimize first-line therapy choice and subsequent sequencing.

Weiterlesen

]]>681Tue, 28 Jul 2026 06:39:05 +0000Understanding Social Drivers of Health Among US Adults with Psoriasis from Different Races and Ethnicities.https://www.psoriasis-news.de/articles.html/1_articles/understanding-social-drivers-of-health-among-us-adults-with-psoriasis-from-different-races-and-ethnicities-r680/IntroductionPsoriasis, a chronic immune-mediated inflammatory skin condition with systemic implications and substantial psychosocial burden, affects individuals across races and ethnicities. This study explored social drivers of health (SDOH), disease burden, and the impact of psoriasis across races and ethnicities.

Methods

An online, cross-sectional survey was conducted among adult US patients with psoriasis (September-December 2023). Participants were recruited through the National Psoriasis Foundation and AmeriSpeak, a national sample panel. Descriptive data were collected using patient-reported outcome measures and questions on disease knowledge, healthcare access and utilization, quality of life (QoL), and social impact. Analyses were stratified by races and ethnicities.

Results

Among 285 participants (mean age 46.7 years; 50.9% male), 68.1% identified as white, 19.3% as Black/African American (BAA), and 20.4% as Hispanic/Latino (H/L). Overall, psoriasis severity was reported as moderate by 36.8% (white: 37.6%, BAA: 25.5%, Asian: 50.0%, and H/L: 27.6%) and severe by 10.2% (white: 8.2%, BAA: 10.9%, Asian: 20.0%, and H/L: 6.9%) of patients. Participants reported moderate QoL impact (Dermatology Life Quality Index [DLQI] mean 10.3), with high burden among H/L (16.6) and BAA (15.1) groups. During flares, 58.6% used prescription medications, with similar rates across races and ethnicities. Transportation barriers were reported by 21.4% overall, more commonly reported by H/L (44.8%) and BAA (34.5%) participants. Difficulty accessing medicine/healthcare was reported by 26.3% overall, particularly white (29.4%) participants. Overall, 29.1% delayed care owing to cultural/linguistic differences, most commonly by BAA and H/L groups. Of the healthcare services requiring partial out-of-pocket payment for treatment of psoriasis, medications were reported as the highest burden by an overall 47.0% of patients (H/L: ~55%, white and BAA ~45%). Overall, only 29.5% received financial assistance.

Conclusions

In this descriptive survey, patients perceived psoriasis as a considerable burden across races and ethnicities. Understanding diversities in patient-reported SDOH and healthcare access issues through culturally competent integrated care may potentially optimize psoriasis outcomes.

Weiterlesen

]]>680Tue, 28 Jul 2026 06:39:05 +0000Short-term response to biologic therapy in psoriatic arthritis (PsA) is not influenced by disease duration at initiation of therapy.https://www.psoriasis-news.de/articles.html/1_articles/short-term-response-to-biologic-therapy-in-psoriatic-arthritis-psa-is-not-influenced-by-disease-duration-at-initiation-of-therapy-r679/ObjectivesWe aimed to determine whether the short-term response to biologics in biologic-naïve psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease course.

Methods

PsA patients who started biologic therapy from the year 2000 to 2025 were included for analysis. Patients considered in the early treatment (ET) group if they started biologic therapy within 2 years of PsA diagnosis, otherwise they were considered in the delayed treatment (DT) group. The primary outcome was ≥50% reduction in the Disease Activity Index for Psoriatic Arthritis (DAPSA) score at 6-months. The secondary outcome was Psoriasis Activity and Severity Index (PASI) 75, defined as ≥75% improvement in the PASI score, at 6-months. Logistic regression was used to examine the association between early treatment and disease outcomes at 6-months. Propensity scores were used to account for differences between the groups at the baseline visit.

Results

Of the 228 included patients, 71 patients were in the ET group and 157 patients in the DT group. There were significant differences in the time from PsA diagnosis to biologic treatments over the decades. The propensity score regression adjusted analysis did not suggest a difference in response at 6 months between those treated within 2 years of diagnosis and those treated later.

Conclusion

Short-term response to biologic therapy in patients with PsA does not appear to differ between those treated early or later in the disease course. It remains to be determined whether early treatment prevents progression of joint damage in the longer-term.

Weiterlesen

]]>679Tue, 28 Jul 2026 06:39:05 +0000